More on ABSI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.07 |
|
|||
| Open | $9.24 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $10.21 | ||||
| Day Low | $9.11 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 5,354,312 | ||||
- AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
- H.C. Wainwright Reiterates Buy Rating on Absci Corp. (ABSI)
- Absci Corp. (ABSI) PT Raised to $20 at KeyBanc
- Form 4 Absci Corp For: Oct 12 Filed by: McClain Sean
- Form 4 Absci Corp For: Oct 12 Filed by: Bedrick Todd
- Form 4 Absci Corp For: Oct 12 Filed by: Jonasson Zachariah
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Guggenheim Reiterates Buy Rating on Absci Corp. (ABSI)
- Absci plans Phase 2 trial of ABS-201 for endometriosis in mid-2027
Entities mentioned with ABSI
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- FDA | View Related Stories »
- Cowen & Co | View Related Stories »
- 13G | View Related Stories »
- Show More...
